九洲藥業(603456.SH):控股股東非公開發行可交換公司債(第一期)將進入換股期
格隆匯5月11日丨九洲藥業(603456.SH)公佈,公司於近日接到控股股東浙江中貝九洲集團有限公司(“中貝集團”)的通知,中貝集團於2019年11月15日完成發行的“浙江中貝九洲集團有限公司2019年非公開發行可交換公司債券(第一期)”將於2020年5月15日進入換股期。
2019年11月15日,“浙江中貝九洲集團有限公司非公開發行2019年可交換公司債券(第一期)”完成發行,債券簡稱“19九01EB”,債券代碼“137093.SH”,發行規模為1.5億元,本期債券的期限為3年期,換股期限自本次可交債發行結束日滿6個月後的第1個交易日起至本次可交債摘牌日前1個交易日止(如為法定節假日或休息日,則順延至下一個交易日)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.